MedTrace Logo

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-07-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

BIOLOGICAL

MEDI5752

MEDI5752

DRUG

Axitinib

INLYTA

DRUG

Lenvatinib

LENVIMA

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • AstraZeneca Early Oncology · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2025-09-26
Completion
2025-09-26
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522323 on ClinicalTrials.gov